Результаты поиска

Optimal Delivery of Follow-Up Care After Allogeneic Hematopoietic Stem-Cell Transplant: Improving Patient Outcomes with a Multidisciplinary Approach.

The increasing indications for allogeneic stem-cell transplant in patients with hematologic malignancies and non-malignant diseases combined with improved clinical outcomes have contributed to increase the number of long-term survivors. However, survivors are at increased risk of developing a unique set of complications and late effects, besides graft-versus-host disease and disease relapse. In this setting, the management capacity of a single health-care provider can easily be overwhelmed. Thus, to provide appropriate survivorship care, a multidisciplinary approach for the long-term follow-up

Do people with disabilities experience disparities in cancer care? A systematic review.

BackgroundOver 1.3 billion people, or 16% of the world's population, live with some form of disability. Recent studies have reported that people with disabilities (PwD) might not be receiving state-of-the-art treatment for cancer as their non-disabled peers; our objective was to systematically review this topic.MethodsA systematic review was undertaken to compare cancer outcomes and quality of cancer care between adults with and without disabilities (NIHR Prospero register ID number: CRD42022281506). A search of the literature was performed in July 2022 across five databases: EMBASE, Medline,

Early integration of palliative care for patients with haematological malignancies.

Early palliative care (EPC) significantly improves quality of life, symptoms, and satisfaction with care for patients with advanced cancer. International organizations have recognized and promoted the role of palliative care as a distinct specialty, advocating its involvement throughout the cancer trajectory. Although patients with haematologic malignancies (HMs) have a comparable symptom burden to patients with solid tumours, they face multiple barriers to EPC integration. In this review, we discuss these barriers, present updated evidence from clinical trials of EPC in HMs and propose models

RANKL/RANK System-Based Mechanism for Breast Cancer Bone Metastasis and Related Therapeutic Strategies.

Breast cancer remains one of the most life-threatening tumors affecting women. Most patients with advanced breast cancer eventually develop metastatic diseases, which cause significant morbidity and mortality. Approximately two-thirds of patients with advanced breast cancer exhibit osteolytic-type bone metastasis, which seriously reduce the quality of life. Therefore, development of novel therapeutic strategies for treating breast cancer patients with bone metastasis is urgently required. The "seed and soil" theory, which describes the interaction between the circulating breast cancer cells (s

Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.

BackgroundPatients with multiple myeloma treated with lenalidomide maintenance therapy have improved progression-free survival, primarily following autologous stem-cell transplantation. A beneficial effect of lenalidomide maintenance therapy on overall survival in this setting has been inconsistent between individual studies. Minimal data are available on the effect of maintenance lenalidomide in more aggressive disease states, such as patients with cytogenetic high-risk disease or patients ineligible for transplantation. We aimed to assess lenalidomide maintenance versus observation in patien

Cancer treatment using peptides: current therapies and future prospects.

This paper discusses the role of peptides in cancer therapy with special emphasis on peptide drugs which are already approved and those in clinical trials. The potential of peptides in cancer treatment is evident from a variety of different strategies that are available to address the progression of tumor growth and propagation of the disease. Use of peptides that can directly target cancer cells without affecting normal cells (targeted therapy) is evolving as an alternate strategy to conventional chemotherapy. Peptide can be utilized directly as a cytotoxic agent through various mechanisms or

ESMO/ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2023.

The European Society for Medical Oncology (ESMO) and ASCO are publishing a new edition of the ESMO/ASCO Global Curriculum (GC) with contributions from more than 150 authors. The purpose of the GC is to provide recommendations for the training of physicians in medical oncology and to establish a set of educational standards for trainees to qualify as medical oncologists. This edition builds on prior ones in 2004, 2010, and 2016 and incorporates scientific advances and input from an ESMO/ASCO survey on GC adoption conducted in 2019, which revealed that GC has been adopted or adapted in as many a

Boron Chemicals in Drug Discovery and Development: Synthesis and Medicinal Perspective.

A standard goal of medicinal chemists has been to discover efficient and potent drug candidates with specific enzyme-inhibitor abilities. In this regard, boron-based bioactive compounds have provided amphiphilic properties to facilitate interaction with protein targets. Indeed, the spectrum of boron-based entities as drug candidates against many diseases has grown tremendously since the first clinically tested boron-based drug, Velcade. In this review, we collectively represent the current boron-containing drug candidates, boron-containing retinoids, benzoxaboroles, aminoboronic acid, carboran

Pomalidomide mitigates neuronal loss, neuroinflammation, and behavioral impairments induced by traumatic brain injury in rat.

BACKGROUND: Traumatic brain injury (TBI) is a global health concern that typically causes emotional disturbances and cognitive dysfunction. Secondary pathologies following TBI may be associated with chronic neurodegenerative disorders and an enhanced likelihood of developing dementia-like disease in later life. There are currently no approved drugs for mitigating the acute or chronic effects of TBI. METHODS: The effects of the drug pomalidomide (Pom), an FDA-approved immunomodulatory agent, were evaluated in a rat model of moderate to severe TBI induced by controlled cortical impact. Post-TBI

Diagnosis and management of osteoporosis in the older senior.

The older senior is at high risk for osteoporosis. It is important for healthcare providers to be fully aware of the potential risks and benefits of diagnosing and treating osteoporosis in the older senior population. Data indicate that bone mineral density testing is under-utilized and drug therapy is often not initiated when indicated in this population. Bone mineral density testing with central dual energy x-ray absorptiometry is essential and cost-effective in this population. All older seniors should be educated on a bone-healthy lifestyle including age-appropriate weight-bearing exercise

Survey of MaineHealth Cancer Care Network Providers on Cannabis Use: Preparation for Studies Sponsored by the National Cancer Institute.

IntroductionCannabis and cannabinoid use in patients with cancer has rapidly scaled up over the past decade and is a topic of considerable clinical, research, and public health interest.MethodsWe conducted a cannabis landscape survey among front-line providers in the MaineHealth Cancer Care Network (MHCCN) before applying and participating in National Cancer Institute (NCI)-sponsored studies on cannabis use in patients with cancer. The results of the survey can better inform participation in national studies and provide a departure point for provider educational activities focused on cannabis

Prevention of medication-related osteonecrosis of the jaw after tooth extraction by local administration of antibiotics and atelocollagen sponge: A preliminary study.

BACKGROUND/PURPOSE: Medication-related osteonecrosis of the jaw (MRONJ) often develops after extraction of a tooth with a local infection. Therefore, it is necessary to develop extraction methods that can prevent MRONJ. Before examining whether antibiotics and atelocollagen administered in the extraction socket can prevent the development of MRONJ after tooth extraction, this study was conducted to determine the appropriate antibiotics concentration and to conduct a clinical study with a small number of cases as a preliminary study. MATERIALS AND METHODS: First, a mixture of minocycline and a

Воздействие причинно-следственных связей между распространенными заболеваниями и провокационными кишечными заболеваниями: исследование по изучению двухнаправленной менделианской случайности.

ЦЕЛИ: Исследования по изучению связей между различными заболеваниями и подстрекательскими кишечными заболеваниями (ИББ) часто ограничиваются путаницей и обратной причиной. Мы стремились оценить потенциальные причинно-следственные связи между широким кругом заболеваний и ИБД, включая болезнь Крона (КД) и язвительный колит (КЮ). МЕТОДЫ: Мы провели всеобъемлющий анализ 104 распространенных болезней и признаков БИ с использованием общего подхода, основанного на обобщенных кратких данных, с использованием метода ОР (МСУГ). Сводные статистические данные о заболеваниях, полученные в рамках общегеноми

Совпадение в полном тексте источника
… Recent targeted Mendelian randomization MR studies have examined selected traits related to IBD, including spleen volume and plant-based food preferences rich in polyphenols, while other MR studies have focused on related gastrointestinal outcomes such as colorectal cancer [ 83 – 85 ]. …

Enhancing Adverse Event Identification and Management in Early-Phase Oncology Clinical Trials: The Emerging Role of Advanced Practice Providers.

BackgroundAdverse events (AEs) are unintended, harmful effects that occur in clinical trials, particularly in early-phase oncology clinical trials (EPOCT), where the risk of adverse effects from experimental therapies is high. Effective AE identification and management are essential for ensuring patient safety, improving outcomes, and advancing research. Advanced practice providers (APPs) play a key role in detecting and managing AEs, serving as a bridge between clinical care and research. However, their full impact on EPOCT remains underexplored.PurposeThis integrative review examines existin

Создание барьеров и возможностей для осуществления программ самостоятельной терапии для пациентов с миломой: протокол качественного декриптационного исследования.

Множественная миелома (ММ) связана с наибольшим симптомным бременем всех гематологовых раковых заболеваний и, несмотря на значительное улучшение методов лечения с высокими показателями реагирования и выживаемости, все еще считается неизлечимой, причем пациенты в течение многих лет проходят многочисленные циклы лечения. Инъекции по подкожному методу (СК) являются распространенным способом доставки для текущей и будущей терапии ММ, при этом данные свидетельствуют о том, что программы, наделяющие пациентов или лиц, занимающихся уходом за больными, ответственностью за управление, могут принести по

Клинический и аналитический мониторинг пациентов с множественным склерозом anti-CD20 :: лечение: исследование по изучению реальных условий безопасности в мире.

ИСТОРИЯ ВОПРОСА: Anti-CD20 Моноклональные антитела являются классом иммуновосприимчивых лекарств, широко используемых при лечении подстрекательских заболеваний центральной нервной системы (СНС), с хорошо зарекомендовавшей себя эффективностью и безопасностью. Хотя эти методы и редки, они могут быть связаны с серьезными неблагоприятными явлениями, включая гематологические и инфекционные осложнения. Целью этого исследования является оценка их характеристик безопасности и терпимости в реальной клинической практике. МЕТОДЫ: Мы провели ретроспективное когортное исследование, в ходе которого пациенты

Fingolimod и риск заболевания раком кожи у лиц с множественным склерозом: протокол когортного исследования на основе популяции.

ВВЕДЕНИЕ: Для изучения последствий рака кожи у лиц с множественным склерозом (MS), обработанных финголимодом, необходимы долгосрочные исследования по вопросам безопасности населения с применением передовых методов установления причинно-следственных связей, в том числе с активным компаратором с дизайном новых пользователей. Цель этого исследования состоит в том, чтобы охарактеризовать протокол изучения взаимосвязи между использованием финголимодов и заболеваемостью раком кожи у лиц с НР. МЕТОДЫ И АНАЛИЗ: Мы будем использовать данные об административном здоровье населения из двух канадских прови

Раскрывая причинно-следственную связь между ожирением и множественным склерозом: систематический обзор литературы.

Множественный склероз (MS) представляет собой многогранное нейродегенеративное расстройство под влиянием генетики и образа жизни. В рамках этого систематического обзора литературы изучается роль six Гены, связанные с ожирением, включая жировую массу и ожирение (FTO), ингибиторную молекулу FAS 2 (FAIM2), тип болезни Ньеманн-пиков C1-like 1 (НПК-1), glucosamine-6-phosphate daminase 2 (ВНПДА2), melanocortin-4 Рецептор (MC4R) и нейротрофический коэффициент, полученный из мозга (BDNF) в контексте MS. МЕТОДЫ: Поиск литературы осуществлялся с использованием баз данных Embase, Scopus, Cochrane, Web of

Association between risk of malnutrition defined by patient-generated subjective global assessment and adverse outcomes in patients with cancer: a systematic review and meta-analysis.

ObjectiveTo assess the association between the risk of malnutrition, as estimated by the Patient-Generated Subjective Global Assessment (PG-SGA) numerical scores, and adverse outcomes in oncology patients.DesignSystematic review and meta-analysis.SettingsA comprehensive search was conducted in PubMed, Web of Science, Embase, CKNI, VIP, Sinomed and Wanfang databases. Studies that examined the association between the risk of malnutrition, as estimated by the PG-SGA numerical scores, and overall survival (OS) or postoperative complications in oncology patients were included. Patients were classif

Talquetamab in multiple myeloma.

Initial results of the phase I trial of talquetamab, a bispecific antibody targeting GPRC5D and CD3, were reported in December of 2022 for the treatment of relapsed or refractory multiple myeloma in the fourth line or later setting. It demonstrated a similar efficacy profile and durability of response to teclistamab, the first bispecific antibody therapy to be approved in multiple myeloma. Additionally, it has less infections than teclistamab but demonstrates unique class-specific side effects including skin, oral, and nail-related adverse events. Despite this, it is still a highly efficacious